Results 1 to 10 of about 1,458 (171)

Effects of Wee1 Inhibitor Adavosertib on Patient-Derived High-Grade Serous Ovarian Cancer Cells Are Multiple and Independent of Homologous Recombination Status [PDF]

Frontiers in Oncology, 2022
ObjectiveA major challenge in the treatment of platinum-resistant high-grade serous ovarian cancer (HGSOC) is lack of effective therapies. Much of ongoing research on drug candidates relies on HGSOC cell lines that are poorly documented. The goal of this
Jaana Oikkonen, Sanna Pikkusaari, Piia Mikkonen   +2 more
exaly   +6 more sources

Phase 2 study of Wee1 inhibitor adavosertib in recurrent uterine carcinosarcoma. [PDF]

Gynecol Oncol Rep
Purpose: Uterine carcinosarcoma (UCS) is a rare but aggressive tumor with high rates of recurrence and poor prognosis, and novel therapies are urgently needed.
Cham S, Xiong N, Tayob N, Krasner C, Wright AA, Lee EK, Sawyer H, Mathews C, Konstantinopoulos PA, Matulonis UA, Liu JF.   +10 more
europepmc   +4 more sources

Pharmacological WEE1 inhibition as a strategy to overcome cisplatin resistance in non-seminoma testicular cancer: insights from preclinical models. [PDF]

Sci Rep
Testicular germ cell tumors are the most common solid malignancy in young adult males with non-seminomatous representing a clinically aggressive subtype.
Tamburello M, Boldini C, Abate A, Salvi V, Valcamonico F, Laganà M, Cosentini D, Suardi NR, Mirabella G, Altieri B, Sigala S.   +10 more
europepmc   +2 more sources

Molecular targeted therapy in combination with chemotherapy for the treatment of platinum-resistant/refractory ovarian cancer (PROC): a systematic review and network meta-analysis. [PDF]

Ann Med
Background Although single-agent chemotherapy is the most common approach for treating platinum-resistant or refractory ovarian cancer (PROC), there is growing evidence that combining molecular targeted agents with chemotherapy is beneficial, especially ...
Ying T, E S, Ying H.
europepmc   +2 more sources

Preclinical drug screen identifies WEE1 inhibitor and vinca alkaloid as a combination treatment concept for Li-Fraumeni syndrome medulloblastoma. [PDF]

iScience
Summary: Li-Fraumeni syndrome (LFS) is characterized by constitutional pathogenic TP53 mutation and increased risk of cancer development, including Sonic Hedgehog-activated medulloblastoma (SHH-MB).
Kolodziejczak AS, Selt F, Peterziel H, Jamaladdin N, Mack N, Maaß K, Meulenbroeks C, Sigaud R, Herold-Mende C, El Damaty A, Burhenne J, Ohmura S, Holland-Letz T, Kutscher LM, Ernst A, Wei PC, Grünewald TGP, Oehme I, Kool M, Jones DTW, Pajtler KW, Kratz CP, Pfister SM, Witt O, Milde T.   +24 more
europepmc   +2 more sources

Comprehensive multi-omics analyses expose a precision therapy strategy that targets replication stress in hepatocellular carcinoma using WEE1 inhibition. [PDF]

J Adv Res
Introduction: Hepatocellular carcinoma (HCC) is an extremely heterogeneous malignancy with a poor prognosis, highlighting the need to target specific vulnerabilities within the tumor during treatment.
Jia X, Zhu X, Chen S, Qiu Q, Song W, Zhang S, Dong H, Li Z, Bian S, Wu H, Dai H, Jin C, Zhou M, Chen J, Xuan Z, Liu P, Zeng Q, Xie H, Zheng S, Song P.   +19 more
europepmc   +2 more sources

PLK1 or WEE1 inhibition targets homologous recombination repair proficiency in BRCA1/2 wild-type high-grade serous ovarian cancer. [PDF]

Cell Death Dis
High-grade serous ovarian cancer (HGSOC) is a poor prognostic disease, especially in BRCA1/2 wild-type (BRCA-WT) patients with homologous recombination (HR) proficiency.
Xi Q, Kunita A, Ogawa M, Kawakami M, Ka M, Nagai S, Duong AQ, Taguchi A, Watanabe K, Fukuda T, Sone K, Shinozaki-Ushiku A, Ushiku T, Hirota Y, Kage H, Katayama K, Oda K.   +16 more
europepmc   +2 more sources

LB-100 Enhances Drugs Efficacy Through Inhibition of P-Glycoprotein Expression in Multidrug-Resistant Glioblastoma and Non-Small Cell Lung Carcinoma Cellular Models. [PDF]

Pharmaceutics
Background/Objectives: This study explores the potential of LB-100 (a protein phosphatase 2A—PP2A inhibitor) combined with adavosertib (a WEE1 kinase inhibitor) and doxorubicin (DOX), to overcome multidrug resistance (MDR) in cancer cells and enhance ...
Podolski-Renić A, Chigriai M, Jovanović Stojanov S, Grozdanić M, Lupšić E, Nikolić I, Dragoj M, Dinić J, Pešić M.   +8 more
europepmc   +2 more sources

Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Adavosertib in Japanese Patients With Advanced Solid Tumors: A Phase I, Open-Label Study

Cancer Treatment and Research Communications
Introduction: We aimed to assess the safety, pharmacokinetic profile, and antitumor activity of adavosertib monotherapy in Japanese patients with advanced solid tumors.
Shunsuke Kondo, Noboru Yamamoto, Kan Yonemori   +2 more
exaly   +3 more sources

LncRNA Wee1-AS coordinates oxidative fatty acid metabolism through the activation of mitochondrial CDK1/CYCLIN B1. [PDF]

Signal Transduct Target Ther
Metabolic dysfunction-associated steatotic liver disease (MASLD) is steadily increasing with life-threatening complications, underscoring the need for new therapeutic targets.
Kim HJ, Jeong C, Lee SH, An S, Hyun GH, Lim GY, Kim JY, Lee J, Park MJ, Kwon SW, Kim W, Noh M, Han YH, Lee MO.   +13 more
europepmc   +2 more sources